Quick Asked: Eloxx Pharmaceuticals Contact Us?

Last update: 02 May, 2024 322 Views

Who is eloxx pharmaceuticals? Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates. We are the leader in the development of eukaryotic ribosomal selective glycosides (ERSG) aimed at treating rare and ultra-rare premature stop codon diseases. This opens in a new window.

What is eloxxs fast track designation? Eloxx Pharmaceuticals, Inc. ( ELOX ), today announced that the U.S. Food and Drug Administration has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. We are delighted to receive Fast Track Designation from the FDA for ELX-02 as the need for patients remains significant.

What is elx 02 ersg? Currently, our lead investigational drug, ELX-02, is a eukaryotic ribosomal selective glycoside (ERSG) designed to restore production of functional proteins, suppress nonsense mutations, and overcome nonsense-mediated decay without the limiting toxicities of aminoglycosides.

Listing Results Eloxx Pharmaceuticals Contact Us? Question Answers